Kornimate/medical-research-clean huggingface dataset:
mg osteocrete post-treatment outcomes

Conditions: Cancer of Bone; Trauma; Aseptic Loosening of Orthopaedic Hardware

Summary: mg osteocrete is a bone substitute used to fill a defect in bone caused by excision of a tumor, orthopaedic hardware that has become loosened, or a trauma-related condition. the aim of this study is to determine the amount of time it takes for bone to heal after treatment with mg osteocrete, and to better understand the efficacy of this treatment through clinical and patient-reported outcomes.

bone voids in the skeletal system can result from trauma, infection, surgery, or oncologic disease. if these voids are not treated, they may lead to issues such as pathological fractures, treatment or hardware failure, and recurrence of disease. various methods exist for addressing bone voids, primarily through the use of grafting materials. autograft-bone harvested from another part of the same patient and transplanted into the void-is considered the "gold standard" because they fulfill all three criteria of the "ideal" void filler: they are osteoconductive, osteoinductive, and osteogenic. however, their use can be limited by availability and potential donor site complications, with up to 39% of patients reporting pain at the donor site. due to concerns with traditional bone grafting methods, there is growing interest in alternative options. while allografts carry a risk of disease transmission and xenografts are prone to immune rejection, synthetic bone graft substitutes offer a promising alternative. these substitutes, made from materials like calcium sulfate or calcium phosphate, address many issues associated with autografts and allografts. with improved understanding of their performance post-implantation, ongoing advancements are being made. this clinical investigation plan outlines an observational study to evaluate clinical and radiographic outcomes with a particular synthetic bone graft substitute (mg osteocrete™; alliant biotech, llc; grand rapids, mi). mg osteocrete™ is a moldable/injectable magnesium-based void filler that provides stability while also increasing cell proliferation. use of mg osteocrete™ has been shown to advance the rate of mineralization with a result of enhanced bone regeneration for multiple types of orthopedic applications.

Eligibility criteria:
inclusion criteria: * 18 years of age and older on the day of surgery * has received or will receive mg osteocrete as a component of their treatment at this institution in accordance with instructions for use for the implanted product * mg osteocrete is indicated for one of the following reasons: 1. as a bone void filler following bone tumor resection, or; 2. as an augment for defects causing aseptic loosening of orthopaedic implants, or; 3. to help substitute bone for trauma-related conditions exclusion criteria: * any contraindication as per instructions for use for mg osteocrete

Keywords: bone defect bone substitute osteocrete
sonu nasal congestion relief study in patients suffering from moderate to severe nasal congestion

Conditions: Nasal Congestion and Inflammations

Summary: to demonstrate the safety and effectiveness of sonu for the treatment of patients suffering from moderate to severe nasal congestion.

sonu consists of and acoustic vibrational headband worn circumferentially at the level of the forehead. a smart phone app, paired to the headband, delivers acoustic resonant frequencies of the subject's nasal cavity through the headband and provides relief. sonu is intended to be used for the treatment of moderate to severe nasal congestion due to rhinitis.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * present with symptoms of nasal congestion for 1 month or more prior to treatment * have a 24 hour reflective nasal congestion subscore of the tnss of 2 or more on a 0 to 3 scale at the time of screening exclusion criteria: * head, nasal or sinus surgery within 3 months * sinus infection diagnosed within the last month, or rhinitis medicamentosa * documented history of nasal polyposis or mass
preliminary percutaneous intervention versus observational trial of arterial ductus in low-weight infants

Conditions: Patent Ductus Arteriosus

Summary: this is a pilot study to collect preliminary data for a larger, multicenter clinical trial proposal. the study will examine two strategies commonly used to treat preterm infants diagnosed with a patent ductus arteriosus (pda). the pda closes after birth for most term infants, but in many preterm infants, it remains open (patent). a pda may present a complication for a number of short-term problems faced by preterm infants. longer-term issues include the development of pulmonary hypertension and changes in the size and performance of the heart. there is ongoing debate as to whether or not the pda requires intervention.

preterm infants diagnosed with a hemodynamically-significant patent ductus arteriosus (hspda) will be included. specific criteria will be followed to determine if a patent ductus arteriosus (pda) is "hemodynamically significant". infants will be randomized to two different approaches for management of the pda. the first will be catheter-based closure (intervention) and the second will be conservative management (non-intervention). both procedures are standard practice at many institutions, including nationwide children's hospital. infants randomized to receive intervention will undergo a procedure in which a catheter is used to place an fda-approved device within the pda, to close it (like a plug). infants randomized to the conservative management (non-intervention) group will be permitted time to see if the pda closes on its own, naturally. however, if the pda remains open and intervention is deemed medically necessary, they will also undergo the catheter closure procedure.

Eligibility criteria:
maximum age (above) indicates qualifying / eligibility criteria. participating infants will be followed until they reach 36 weeks corrected gestational age or are discharged from the hospital, whichever comes first. inclusion criteria: * preterm infants ≤28 weeks gestational age with hemodynamically-significant patent ductus arteriosus (pda) at 2 - 4 weeks of age. * body weight greater than or equal to 700 grams exclusion criteria: * significant genetic (ex.- trisomy) or physiological (ex. - omphalocele) abnormalities * other cardiac disease not including atrial-septal defects or ventricular septal defects (ex. tetrology of fallot, single ventricle physiology) * body weight less than 700 grams

Keywords: catheter closure conservative treatment percutaneous closure
standardized physical activities measured by accelerometers

Conditions: Transient Ischemic Attack

Summary: standardized physical activities measured by accelerometers background and aims: physical activity may be assessed by several different methods. however, the use of accelerometers is the most direct method available for real-time measurements. the piezoelectric element of accelerometers records an electric voltage during movement which is then transcribed to activity counts (ac). few studies have used actical accelerometers to assess standardized physical activities and most of these were not applicable to patients in a hospital setting. no previous studies have applied actical accelerometers to the wrists or ankles during standardized activities. the aim of this study is to record ac during different standardized activities frequently done by patients hospitalized for acute ischemic stroke. methods: patients discharged since february 2012 after a transient ischemic attack have been invited to participate in the study scheduled for june-september 2012 (nexpected=25). all participants wear 5 accelerometers (actical), one at each wrist and ankle and one over the hip. standardized physical activities include: * treadmill walking (5 minutes, 1 and 4km/h) * staircase walking (1 floor, normal pace) * cycling with fixed load (5 minutes) * standing up from sitting position and sitting down again (x5) * standing up from supine position * turning from left to right and back while lying in bed * raising outstretched arm 90° (x5, standing position) * eating (5 minutes, sitting position) * drinking a glass of water * sleeping (6 hours)


Eligibility criteria:
inclusion criteria: * previous transient ischemic attack * age \> 18 years exclusion criteria: * pregnancy and lactation * time limit of more than 2 days of standardized activities exceeded * no informed consent * disability when tested with scandinavian stroke scale (score \ 0), modified rankin scale (score \>0) and barthels index 100 (score \<100)
characterizing the association between preoperative depressive symptoms and opioid use/misuse after surgery

Conditions: Opioid Use

Summary: this observational study aims to characterize the relationship between preoperative depressive symptoms and opioid use/ misuse after surgery using a perioperative learning health care system. we will follow a prospective cohort of patients undergoing elective surgery.


Eligibility criteria:
inclusion criteria: 1. age 18+ 2. planning to undergo surgery 3. english speaking 4. ability and willingness to complete questionnaires and assessments exclusion criteria: 1. any conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) 2. known pregnancy 3. elevated suicidality 4. enrollment in a conflicting perioperative trial
near infrared spectroscopy in patients undergoing robotic assisted laparoscopic surgery in the trendelenburg position

Conditions: Nontraumatic Compartment Syndrome of Leg

Summary: some robotic endoscopic surgeries require a steep trendelenburg position and a carbon dioxide pneumoperitoneum. this minimally invasive approach has the advantages of less postoperative pain, shorter hospital stay and faster recovery. after prolonged operative time in a trendelenburg position rare but significant complications are a cerebral oedema or a well leg compartment syndrome. well leg compartment syndrome results from inadequate perfusion in the lower limbs and the perfusion pressure is decreased proportionally to the lower extremity elevation. the condition can lead to release of intracellular proteins and myoglobinuria, hyperpotassaemia and metabolic acidosis followed by cell necrosis. the risk for tissue damage increases after 4 hours in a trendelenburg position. if not promptly diagnosed and treated, a compartment syndrome has devastating complications like permanent dysfunction, limb loss, renal failure or even death. there are no specific guidelines for diagnosis and for the timing of surgical decompression. fasciotomy is a clinical decision. there is no universal agreement at which compartment pressure irreversible muscle damage occurs. the only objective diagnostic tool available is currently to measure the intramuscular pressure, however this is invasive, painful and may yield unreliable results. an intracompartment pressure of 0- 10mm hg is the normal range. near infrared spectroscopy (nirs) monitors are validated and approved to measure cerebral and somatic tissue oxygenation below the sensors and may help detecting promptly a compartment syndrome. therefore, the investigators designed the present study to detect a change in the tissue oxygenation in the lower legs during robotic assisted, laparoscopic surgery in the trendelenburg position.


Eligibility criteria:
inclusion criteria: * patients scheduled for robotic assisted laparoscopic surgery in a trendelenburg position exclusion criteria: * preexisting moderate neurological disease * moderate cerebrovascular disease * coronary disease with angina pectoris (ccs ≥ 1) * peripheral arterial disease ii (with intermittent claudicatio) * cardiac insufficiency (nyha \>2) * tumour in pharynx, larynx or oesophagus, an aneurysm of the thoracic aorta

Keywords: near infrared spectroscopy somatic saturation well leg compartment syndrome robotic assisted laparoscopic surgery trendelenburg position
treatment outcomes after receiving conventional clasp or precision attachment removable partial dentures.

Conditions: Bilateral Edentulous Mandible (Kennedy Class I)

Summary: picots: p: kennedy class і patients i : mandibular removable partial denture with ot cap attachment c: mandibular removable partial denture with gingival approaching clasp assembly o: 1ry outcome: oral health related quality of life 2ry outcome: biting force t: 1 year s : randomized control trial research question: in kennedy class і patients will the removable partial denture with ot cap attachment compared to conventional removable partial denture with clasp assembly results in difference in oral health related quality of life of patients?

in bilateral edentulous mandible with missing molars, the clasp retained partial denture will be compared with precision attachment partial denture for better quality of life for patients.

Eligibility criteria:
inclusion criteria: 1. patients with mandibular free end saddle cases. 2. patients less than 75 years old. 3. patients who approved to be included in the trial and signed the informed consent. 4. patients are not suffering from diabetes mellitus. exclusion criteria: 1. patients are suffering from diabetes mellitus. 2. patients above 75 years old. 3. patients are receiving chemotherapy or radiotherapy. 4. patients with severe temporomandibular joint problems. 5. patients who refused the trial.

Keywords: kennedy classification for edentulous ridge
group versus individuals telehealth exercise programs for people with parkinson disease

Conditions: Parkinson Disease

Summary: this study will compare the impact of physical therapist led telehealth exercise programs on people with parkinson disease. eligible participants will complete this program individually or in a group of 9 other participants. the impact of participation in this program on motor function, postural control, gait, quality of life, and self-efficacy for exercise will be measured.

this program will be delivered 2 times per week for 8 weeks with examination of outcome measures prior to and after completion. the investigators plan to enroll 20 participants with 10 completing a group program led by a physical therapist and 10 completing an individual exercise program led by a physical therapist.

Eligibility criteria:
inclusion criteria: * have a diagnosis of idiopathic parkinson disease * been prescribed a stable dose of levadopa medication for at least 4 weeks prior to study participation * be able to walk independently * have a referral from a physician to participate in the program * have access to a computer/tablet/or phone to use for telehealth sessions with reliable internet and access to the zoom platform exclusion criteria: * have any other neurological condition other than parkinson disease * have a score less than 20/28 on the mini-balance systems evaluation test (reflecting a higher risk of falls) * demonstrate unstable/unsafe blood pressure or heart rate responses during the initial evaluation with response to submaximal exercise * have any musculoskeletal condition that affected their ability to participate in the exercise group * score less than 24/30 on the mini mental status examination during the initial evaluation
secondary intervention and surveillance after evar

Conditions: Abdominal Aortic Aneurysm Without Rupture

Summary: this is a retrospective cohort study of consecutive patients submitted to elective evar, between february/2009 and may/2019 in a single institution. symptomatic or ruptured aaa, mycotic aneurysms, isolated iliac aneurysms and complex abdominal aortic repairs were excluded. the primary outcomes were freedom from secondary intervention and compliance with follow-up, defined as surveillance imaging performed within a periodicity no longer than 18 months.


Eligibility criteria:
inclusion criteria: * this is a retrospective cohort study of consecutive patients submitted to elective evar, between february/2009 and may/2019 in a single institution. exclusion criteria: * symptomatic or ruptured aaa, mycotic aneurysms, isolated iliac aneurysms and complex abdominal aortic repairs were excluded.
effect of chitosan-n-acetylcysteine on subjective pain sensation in corneal abrasion

Conditions: Eye Diseases

Summary: aim of this study is to investigate the effect of chitosan-n-acetylcysteine (c-nac; lacrimera®, croma-pharma gmbh, leobendorf, austria) in patients with corneal abrasion less than one third of the corneal surface on subjective pain sensation.

commonly, standard of care for corneal abrasion is topical antibiotics. bandage contact lenses may be used in addition, which significantly decrease pain sensation in a vast majority of patients. recently, a new preservative-free agent consisting of a novel biopolymer, chitosan-n-acetylcysteine (c-nac; lacrimera®, croma-pharma gmbh, leobendorf, austria) has been approved for the treatment of dry eye syndrome (des). this agent electrostatically binds to the mucine layer of the tear film, forming a glycocalyx-like structure. in an animal model, the beneficial effect of chitosan-n-acetylcysteine on recovery time has been observed. aim of this study is to investigate the effect of chitosan-n-acetylcysteine (c-nac; lacrimera®, croma-pharma gmbh, leobendorf, austria) in patients with corneal abrasion less than one third of the corneal surface on subjective pain sensation. it will further explore the extend of corneal healing after use of lacrimera® over 5 days in those patients initially treated with lacrimera®.

Eligibility criteria:
inclusion criteria: * age older than 18 years * corneal abrasion less than one third of the cornea exclusion criteria: * ocular surgery within prior 3 months in the affected eye * ocular injury within prior 3 months before abrasion in the affected eye * ocular herpes of eye or eyelid within prior 3 months * active ocular infection * active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * ocular surface abnormality that may compromise corneal integrity * presence of diseases that reduce experience of pain (e.g. diabetes mellitus) * pregnancy
uveal melanoma and brachytheraphy: long-term outcomes.

Conditions: 106 Ruthenium Plaque Brachytherapy; Uveal Melanoma

Summary: this study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing ru-106 plaque brachytherapy between february 2011 and march 2020


Eligibility criteria:
inclusion criteria: * age older than 40 years * diagnosis of uveal melanoma exclusion criteria: * age older than 80 years * no diagnosis of uveal melanoma
the removing port of the laparoscopic cholecystectomy material

Conditions: Wound Infection

Summary: laparoscopic cholecystectomy is gold standard for gallstones. in this study the investigators are investigating the effect of the removing of cholecystectomy material from different ports, to the port site infections.

laparoscopic cholecystectomy is gold standard for gallstones. but there is no consensus about which port place is optimal for the removing of the cholecystectomy material from the abdomen. there are different port site infections rates in the literature. the minimal tissue damage of laparoscopic cholecystectomy suggests a lower risk of wound infection, but there are series with an infection range of 8 %. the investigators are investigating is there any difference at the port site infection rates when the cholecystectomy material removed from different ports from the abdomen at the laparoscopic cholecystectomy.

Eligibility criteria:
inclusion criteria: * subject has cholelithiasis exclusion criteria: * subject has perforated gallbladder * subject has malignancy * subject has increasing wall thickness of the gallbladder * subject has malignancy in the preoperative ultrasonography in the gallbladder * subject has pregnancy

Keywords: port infection cholecystectomy
tc-99m renography and cisplatin-induced nephrotoxicity

Conditions: Cancer; Drug Toxicity; Kidney Failure

Summary: cisplatin is a heavy-metal complex widely used in the treatment of a variety of malignancies, including small cell and non-small cell lung cancer, ovarian, bladder, head and neck, esophageal, cervical and germ cell tumors. the administration of cisplatin is commonly associated with certain drug-induced toxicities that may limit their clinical utility and adversely affect the quality of life of patients undergoing treatment. although many advances have been made in reducing some of the toxicities associated with platinum drug therapy, it is clear that dose-limiting nephrotoxicity remains a major stumbling block in the use of this compound. subtle changes in renal function occur without overt renal insufficiency, consisting of a decrease in effective renal plasma flow and tubular dysfunction despite aggressive hydratation. early tubular damage occurring within 1 to 3 hours after cisplatin administration has been demonstrated by measurement of urinary beta 2-microglobulin, a sensitive marker of tubular injury. the chronic lesion has become of greater concern in recent years as many patients have been cured or placed into long-term remission due to cisplatin treatment. it consists of a decrease in glomerular filtration rate, which is not necessary characterized by a remarkable increase in serum creatinine. cumulative tubular damage has been demonstrated by increased urinary excretion of tubular enzymes such as alanine aminopeptidase and beta 2-microglobulin. in this setting, predicting the occurrence of chronic cisplatin-induced nephrotoxicity remains a clinical challenge. tc-99m mercaptoacetyltriglycine (mag3) is predominantly a proximal tubular secretion renal agent without cortical fixation indicated for dynamic renal studies to evaluate cortical tubular function and collecting system drainage. tc-99m mag3 and is the agent of choice for obstructive uropathy and diffuse functional abnormalities of the renal cortex. the aim of this study was to evaluate by means of tc-99m mag3 scintigraphy the acute and subacute impairment of tubular secretion after cisplatin administration in patients with head and neck cancer receiving chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with head and neck cancer * receiving a chemotherapy including cisplatin administration (\>80 mg/m2) * who score \< or = 2 * estimated life expectancy \> 6 month * normal renal function * signed informed consent exclusion criteria: * congestive heart failure * history of cisplatin treatment * metastatic carcinoma * history of radiation therapy * history of renal insufficiency * history of chronic renal disease * pregnancy

Keywords: technetium tc 99m mertiatide radionuclide imaging cisplatin kidney failure drug toxicity cancer